Company news
Neuraxis, Inc. (AMEX:NRXS) news
Neuraxis, Inc. news releases on 6ix. Latest, Sep 29, 2026: NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief…
Press releases & updates
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
September 29, 2026
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
September 16, 2026
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
September 16, 2026
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
August 11, 2026
NeurAxis Expands Payer Coverage with New Policies
August 4, 2026
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
May 12, 2026
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
May 5, 2026
NeurAxis Expands Payer Coverage with Four New Medical Policies
April 22, 2026
NeurAxis, Inc. Announces Preferred Stock Dividend
April 10, 2026
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
March 19, 2026
NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026
March 12, 2026
NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway
January 8, 2026
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
December 19, 2025
NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain
December 1, 2025
NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives
November 12, 2025
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
November 11, 2025
NeurAxis : Quarterly Report for Quarter Ending September 30. 2025 (Form 10-Q)
November 10, 2025
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025
November 4, 2025
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
October 24, 2025
NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 18, 2025
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
August 12, 2025
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
August 5, 2025
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
June 17, 2025
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
June 10, 2025
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
May 27, 2025
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
May 22, 2025
NeurAxis Announces $5.0 Million Registered Direct Offering
May 21, 2025
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms
May 20, 2025
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
May 12, 2025
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
May 5, 2025